Company Filing History:
Years Active: 2023-2025
Title: The Innovative Contributions of Wendy Cross
Introduction
Wendy Cross is a notable inventor based in Middlesex, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of highly purified compounds. With a total of 3 patents to her name, her work has had a substantial impact on the industry.
Latest Patents
Wendy's latest patents include methods for producing highly purified batches of pharmaceutical grade migalastat and methods for purifying intermediate grade migalastat hydrochloride. Additionally, she has developed methods for producing [(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride (lucerastat hydrochloride) and other 1-deoxygalactonojirimycin compounds. These innovations also encompass methods for purifying intermediate grade lucerastat hydrochloride and other related compounds.
Career Highlights
Wendy Cross is currently associated with Amicus Therapeutics, Inc., where she continues to advance her research and development efforts. Her work focuses on creating effective pharmaceutical solutions that address critical health issues.
Collaborations
Wendy has collaborated with esteemed colleagues such as James Cartwright and Clive King, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Wendy Cross exemplifies the spirit of innovation in the pharmaceutical industry through her groundbreaking patents and collaborative efforts. Her contributions are paving the way for advancements in drug development and purification methods.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.